PRTA

Prothena Corporation plc (PRTA) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Prothena is a late-stage clinical biotechnology company focused on protein dysregulation, developing therapies for neurodegenerative and rare peripheral amyloid diseases. The company operates as a single segment and maintains strategic collaborations with Roche, Bristol Myers Squibb (BMS), and Novo Nordisk.

Key Financial Metrics

Restructuring Costs: The company incurred $32.6 million in restructuring charges for the quarter and year-to-date, primarily related to workforce reduction and contract terminations following the discontinuation of the birtamimab program.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by 97% in Q2 2025 compared to Q2 2024. The prior year included a one-time $132.0 million recognition from the expiration of research terms under the BMS collaboration agreement. Current revenue is driven by the ongoing PRX019 Phase 1 clinical trial obligation.
• Net Loss vs. Income: The company reported a net loss of $125.8 million in Q2 2025, a significant shift from the $66.9 million net income reported in Q2 2024. This was driven by the loss of the large BMS revenue recognition, increased restructuring costs, and a $44.8 million income tax expense.
• Income Tax Provision: A $44.8 million tax expense was recorded in Q2 2025 due to the establishment of a full valuation allowance against federal deferred tax assets, reversing the tax benefit seen in the prior year.
• Operating Expenses: R&D expenses decreased by 30% ($17.0 million) quarter-over-quarter due to lower clinical trial and manufacturing costs, partially offset by the new restructuring line item.

Guidance, Outlook, and Risks

• Liquidity: Management believes cash and cash equivalents of $371.4 million are sufficient to fund operations for at least the next 12 months. The company expects to require additional capital for future development and commercialization.
• Program Updates:
  • Prasinezumab (Roche): Partner Roche announced advancement into Phase 3 development for early-stage Parkinson's disease following positive Phase 2b PADOVA study data.
  • PRX012 (Alzheimer's): Phase 1 data is expected to be reported in August 2025.
  • Birtamimab: Development was discontinued in May 2025 after the Phase 3 AFFIRM-AL trial failed to meet primary endpoints, triggering the restructuring plan.
• Restructuring: The company announced a ~63% workforce reduction in June 2025 to align costs with remaining programs. Substantially all cash payments related to the $32.6 million restructuring charge are expected by Q4 2025.
• Risks: Key risks include the need for additional financing, dependence on third-party collaborators (Roche, BMS, Novo Nordisk) for development and commercialization, and the inherent uncertainty of clinical trial outcomes.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $371.4 million cash balance against the projected $170-$178 million full-year 2025 cash burn rate.
• Restructuring Execution: Monitor the timeline for the $30.3 million restructuring liability payout and the impact of the 63% workforce reduction on operational capacity.
• PRX012 Data Readout: Confirm the timing and results of the anticipated August 2025 Phase 1 data release for the Alzheimer's candidate.
• Collaboration Milestones: Track progress on Roche's Phase 3 prasinezumab trial and BMS's Phase 2 BMS-986446 trial, as these are critical for future non-dilutive funding.
• Tax Position: Review the implications of the new valuation allowance on future tax benefits and the impact of recent U.S. tax reform legislation mentioned in the filing.